Monday, January 22, 2018 1:29:11 PM
You can look it up yourself. If they had a problem the SEC would not send this letter.
https://www.sec.gov/Archives/edgar/data/1438943/000000000017035911/0000000000-17-035911-index.htm Mail Stop 3561
Via E-mail
Robert Brooke
Chief Executive Officer
Vitality Biopharma, Inc.
1901 Avenue of the Stars, 2nd Floor Los Angeles, California 90067
Re: Vitality Biopharma, Inc. Registration Statement on Form S-1 FiledSeptember13,2017
File No. 333-220446
Dear Mr. Brooke:
October 10, 2017
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Killoy at (202) 551-7576 with any questions.
cc: Mark C. Lee, Esq. Greenberg Traurig, LLP
Sincerely,
/s/ James Lopez (for)
John Reynolds
Assistant Director
Office of Beverages, Apparel, and Mining
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM